Dr Ann Marie Pope PhD BSc(Hons)

Institute of Cancer and Genomic Sciences
Trial Co-Ordinator

Contact details

Telephone
+44 (0)121 414 6372
Fax
+44 (0)121 414 3320
Email
a.m.pope@bham.ac.uk
Address
Institute of Cancer and Genomic Sciences
College of Medical and Dental Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Qualifications

  • PhD - Bioprocess Engineering, University of Birmingham, 2005
  • BSc (Hons) - Applied Biochemistry, John Moores University, Liverpool, 2000

Publications

Tan WS, Panchal A, Buckley L, Devall AJ, Loubière LS, Pope AM, Billingham LJ & Kelly JD et al.  Radiofrequency-induced thermo-chemotherapy effect versus a second course of Bacillus Calmette-Guérin or institutional standard in patients with recurrence of non–muscle-invasive bladder cancer following induction or maintenance Bacillus Calmette-Guérin therapy (HYMN): a phase III, open-label, randomised controlled trial. European Urology, 28 Sep 2018. DOI: 10.1016/j.eururo.2018.09.005

James ND, Pirrie SJ, Pope AM, et al. Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: The trapeze randomized clinical trial. JAMA Oncology. Jan 2016;2(4):493-9. DOI: 10.1001/jamaoncol.2015.5570

James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I, et al. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technol Assess. July 2016;20(53). DOI: 10.3310/hta20530

Andronis L, Goranitis I, Pirrie S, Pope A, Barton D, Collins S, et al. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International. July 2016. DOI: 10.1111/bju.13549

Wadhwa VK, Wen K, Pirrie S, Pope AM, James ND. The use of serum markers in prediction of survival in the TRAPEZE factorial trial evaluating docetaxel with zoledronic acid, strontium-89 or both in castrate-refractory prostate cancer (CRPC) metastatic to bone. ASCO Annual Meeting; 2013; Chicago, USA.  http://meetinglibrary.asco.org/record/86752/abstract; http://meetinglibrary.asco.org/record/86752/poster 

James ND, Pirrie SJ, Pope AM, et al. Clinical outcomes and survival following treatment of metastatic castrate-refractoryprostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: The TRAPEZE randomized clinical trial. ASCO General Meeting. 8 Jul 2013; Chicago, USA.  http://meetinglibrary.asco.org/record/110280/abstract

James ND, Pirrie SJ, Pope AM, et al. Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: The trapeze randomized clinical trial. NCRI Cancer Conference; 3-6 Nov 2013; Liverpool. UK.  http://conference.ncri.org.uk/abstracts/2013/abstracts/A73.htm

James ND, Pirrie SJ, Pope AM, et al.  Initial feasibility and safety results from a phase II/III clinical trial to evaluate docetaxel therapy in combination with zoledronic acid +/- strontium-89 in hormone-refractory prostate cancer patients. ASCO Genitourinary Cancers Symposium; 2009; Orlando, USA. http://meetinglibrary.asco.org/content/20302-64